- Conditions
- HIV
- Interventions
- ibalizumab, Optimized Background Regimen (OBR)
- Biological · Drug
- Lead sponsor
- TaiMed Biologics Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 27
- States / cities
- Long Beach, California • Los Angeles, California • Palm Springs, California + 18 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–5
of 5
matching trials from the live ClinicalTrials.gov search.
- Conditions
- HIV Infections, Multi-Antiviral Resistance
- Interventions
- No ibalizumab or Pre-ibalizumab treatment, On ibalizumab treatment
- Other · Biological
- Lead sponsor
- Theratechnologies
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 168 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 36
- States / cities
- Los Angeles, California • Palm Springs, California • San Diego, California + 22 more
- Conditions
- HIV
- Interventions
- ibalizumab, Optimized Background Regimen
- Drug
- Lead sponsor
- TaiMed Biologics Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 79 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 31
- States / cities
- Long Beach, California • Los Angeles, California • Palm Springs, California + 21 more
- Conditions
- HIV-1-infection
- Interventions
- Bictegravir, Lenacapavir, BIC/LEN FDC, Stable Baseline Regimen
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 689 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2028
- U.S. locations
- 40
- States / cities
- Berkeley, California • Beverly Hills, California • Los Angeles, California + 34 more
- Conditions
- HIV-1-infection
- Interventions
- ibalizumab-uiyk
- Drug
- Lead sponsor
- TaiMed Biologics Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 43 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2022
- U.S. locations
- 4
- States / cities
- Los Angeles, California • Fort Lauderdale, Florida • Orlando, Florida + 1 more